<DOC>
	<DOCNO>NCT00621881</DOCNO>
	<brief_summary>This open-label study compare pharmacokinetic safety effect naproxcinod hepatic impaired patient vs. match healthy subject .</brief_summary>
	<brief_title>A Phase 1 Study Compare PK Safety Naproxcinod Hepatic Impaired Patients Matching Healthy Subjects</brief_title>
	<detailed_description>This open-label , non-randomized , parallel-group study conduct two study site . Patients hepatic impairment match healthy subject receive naproxcinod 750 mg bid 6 day qd last day .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Male Female , age 40 75 year stable hepatic insufficiency conform ChildPugh classification B OR Male Female , age 40 75 year similar distribution age , weight , gender , smoke habit , race , general good health Current expect use anticoagulant analgesic , antiinflammatory therapy except lose dose aspirin History renal impairment Diagnosis gastric duodenal ulceration and/or history significant gastroduodenal bleeding within last 6 month Clinically relevant abnormal ECG Alcohol drug abuse within last 6 month Any significant chronic disease ( except hepatic insufficiency patient cohort ) may interfere study evaluation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hepatic impairment</keyword>
</DOC>